Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Cancer
Interventions: selenomethionine, finasteride, placebo; Dietary Supplement · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions: 18F-DCFPyL; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: Lenalidomide, Docetaxel, Prednisone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: New York, New York

Conditions: Hot Flashes
Interventions: Isoflavone, Placebos; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older · Male only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Prostate Cancer
Interventions: PACE with Cabazitaxel (15 mg/m2), PACE with Cabazitaxel (20 mg/m2); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Adenocarcinoma of Prostate, Radical Prostatectomy, Hepatocellular Carcinoma (HCC), Glioma, Renal Cell Carcinoma (RCC), Prostate Cancer
Interventions: [18F]DCFPyL, PET/MRI scanner; Drug · Radiation
Lead sponsor: Ciprian Catana, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Abiraterone acetate 1000 mg po daily, Cabazitaxel 25 mg/m2 IV, prednisone 5 mg po BID; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 4
States / cities: New York, New York • Philadelphia, Pennsylvania • Norfolk, Virginia

Conditions: Hormone Refractory Prostate Cancer
Interventions: AT-101; Drug
Lead sponsor: Ascenta Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Greenbrae, California • New Haven, Connecticut • Memphis, Tennessee + 1 more

Conditions: Prostate Cancer
Interventions: survey administration; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 35 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: Biopsy; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: walnuts, usual diet, phone counseling with dietitian; Other
Lead sponsor: Stephen Freedland; Other
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer Screening, Colon Cancer Screening, Prostate Cancer Screening
Interventions: Decision aid; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma, Prostate Adenocarcinoma
Interventions: PEG-BCT-100; Biological
Lead sponsor: Bio-Cancer Treatment International Limited; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: San Diego, California • Santa Monica, California

Conditions: Prostatic Neoplasms, Prostatic Diseases, Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent
Interventions: 68GA PSMA-HBED-CC; Drug
Lead sponsor: Jeanne Link; Other
Eligibility: 18 Years and older · Male only
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Cancer, Pneumoperitoneum
Interventions: AirSeal System, Standard Endopath; Device
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years and older · Male only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Apalutamide, Degarelix, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Drug · Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Conditions Influencing Health Status, Healthy, Prostate Cancer
Interventions: laboratory biomarker analysis, transrectal prostate biopsy; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 243 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2027
U.S. locations: 5
States / cities: Arcadia, California • Duarte, California • Glendora, California + 2 more

Conditions: Prostate Cancer
Interventions: Surveillance; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Metastatic Castration-resistant Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions: Abemaciclib, Lutetium Lu 177-PSMA-617; Drug
Lead sponsor: Vadim S Koshkin; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer
Interventions: 5-Azacitidine, all trans retinoic acid, Lupron; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy
Interventions: Hypofractionated radiation with a microboost; Radiation
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Laboratory Biomarker Analysis, Placebo, Tivantinib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 20
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 14 more

Conditions: Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
Interventions: ²¹²Pb-DOTAM-GRPR1; Drug
Lead sponsor: Orano Med Theranostics, SAS; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 8
States / cities: Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more

Conditions: Prostate Cancer
Interventions: Urine collection and blood draw; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer

Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy

Phase I Trial of PACE for Metastatic Prostate Cancer

Multimodal Machine Learning Characterization of Solid Tumors

Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Frequency of Prostate-Specific Antigen Screening in African American Men in the San Francisco Area

Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer

WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy

Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions

Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors

Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

Study of Carbon Dioxide Exchange Patterns During Robotic Prostatectomies

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome

Ketogenic Diet and Prostate Cancer Surveillance Pilot

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Cancer DNA Detection in Blood and Urine